Cardiovascular (CV) disease is the leading cause of mortality in the US and globally contributing to more than 17 million deaths worldwide. For years, lowering LDL-cholesterol has been one of the primary targets for reducing CV risk, with statins as the established treatment. Recently, new science has emerged and is changing the landscape of how cardiologists and the broader CV team reduce CV risk in their patients. The goal of this page is to provide a resource to highlight the most relevant content on the emerging science in CV risk beyond LDL. Curated content will include new cutting-edge science along with foundational policy, education, and tools.

Supported by:

Guidelines and Policy

Journal Scans

Clinical Tools and Patient Resources:

Expert Analysis:

Patient Cases:

Other Articles:

Images and Slides: